ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.

Yi, Ming; Li, Anping; Zhou, Linghui; Chu, Qian; Luo, Suxia*; Wu, Kongming*浙江大学; 郑州大学
Cancer Immunol Immunother2021-6DOI: 10.1007/s00262-020-02817-z
10阅读
引用收藏
分享

摘要

BACKGROUND: Lung adenocarcinoma (LUAD) is a common pulmonary malignant disease with a poor prognosis. There were limited studies investigating the influences of the tumor immune microenvironment on LUAD patients' survival and response to immune checkpoint inhibitors (ICIs). METHODS: Based on TCGA-LUAD dataset, we constructed a prognostic immune signature and validated its predictive capability in the internal as well as total datasets. Then, we explored the differences of tumor-infiltrating lymphocytes, tumor mutation burden, and patients' response to ICI treatment between the high-risk score group and low-risk score group. RESULTS: This immune signature consisted of 17 immune-related genes, which was an independent prognostic factor for LUAD patients. In the low-risk score group, patients had better overall survival. Although the differences were non-significant, patients with low-risk scores had more tumor-infiltrating follicular helper T cells and fewer macrophages (M0), which were closely related to clinical outcomes. Additionally, the total TMB was markedly decreased in the low-risk score group. Using immunophenoscore as a surrogate of ICI response, we found that patients with low-risk scores had significantly higher immunophenoscore. CONCLUSION: The 17-immune-related genes signature may have prognostic and predictive relevance with ICI therapy but needs prospective validation.

学科与关键词

关键词
Immune checkpoint inhibitorImmunotherapyLung adenocarcinomaPrognostic modelThe tumor immune microenvironmentTumor mutation burden
相关
加载中…
  • CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma
    Zhang, Minghui; Ma, Jianli; Guo, Qiuyue; Ding, Shuang; Wang, Yan; Pu, Haihong*Frontiers in Immunology, 2022, 13: 806877.被引 12
  • Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma
    Cao, Kui; Liu, Mingdong; Ma, Keru; Jiang, Xiangyu; Ma, Jianqun*; Zhu, Jinhong*Cancer Immunology, Immunotherapy, 2022, 71(6): 1295-1311.被引 14
  • A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments
    Wang, Chenghao; Lu, Tong; Xu, Ran; Chang, Xiaoyan; Luo, Shan; Peng, Bo; Wang, Jun; Yao, Lingqi; Wang, Kaiyu; Shen, Zhiping; Zhao, Jiaying*; Zhang, Linyou*Journal of Thoracic Disease, 2022, 14(6): 2131-+.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Cancer Immunol Immunother
发表日期
2021-06
卷期
第 70 卷, 第 6 期
页码
1705-1719
DOI
10.1007/s00262-020-02817-z
成果收录
PUBMED

作者

  • Y

    Yi, Ming (第一作者)

  • L

    Li, Anping

    zhengzhou university

查看全部 6 位作者收起作者
  • Z

    Zhou, Linghui

    zhejiang university

  • C

    Chu, Qian

    zhengzhou university

  • L

    Luo, Suxia (通讯)

    zhengzhou university

  • W

    Wu, Kongming (通讯)

    zhengzhou university

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417